INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10782968				
Filing Date		2004-02-20				
First Named Inventor	Willia	ms				
Art Unit		1643				
Examiner Name	Harris	Dent, Ph.D.				
Attorney Docket Number		W1107/20009				

U.S.PATENTS Remove											
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	)ate	of cited Document Relev			es,Columns,Lines where es,Appear		
	1	5770563	B1	1998-06	6-23	Roberts					
If you wish to add additional U.S. Patent citation information please click the Add button.						Add					
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ition	of cited Document				Lines where ges or Relev	
	1										
If you wish to add additional U.S. Published Application citation information please click the Add button. Add											
				FOREIG	3N PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	or /	where Rel	or Relevant	T5
	1										
If you wish to add additional Foreign Patent Document citation information please click the Add button Add											
NON-PATENT LITERATURE DOCUMENTS Remove											
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), nublished, city and/or country where published.									T5		

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10782968		
iling Date		2004-02-20		
irst Named Inventor	Willia	ms		
Art Unit		1643		
xaminer Name	Harris			
Morney Docket Number		W1107/20009		

	1	Shafiee A et al., Inhibition of Retinal Angiogenesis by Peptides Derived Sci. 2000; 41: 2378-2388.	from Thrombospondin	-1. Invest Opthamol Vis	
	2	Hugo CPM et al., Thrombospondin peptides are potent inhibitors of me proliferation in vitro and in vivo. Kidney International. 1999; 55: 2236-22		endothelial cell	
	3	Taraboleti G et al.; The heparin binding 25 kDa fragment of thrombosgelatinase and TIMP-2 production in endothelial cells. The Faseb Joun			
	4	Damas C et al., The 33-kDa Platelet α-granule Membrane Protein (GM Thromobospondin. Thromobosis and Haemostasis. 2001; 86: 887-893.	P-33) is an N-terminal	Proteolytic Fragment of	
	5	Kurol K et al.; Circulating angiogenesis regulators in cancer patients.	int J Biol Markers. 200	1; 16: 5-26.	
	6	Morandi V et al.; Characterization of a novel monoclonal antibody (V58 heparin-binding fragment of human endothelial cell thrombospondin. Fi			
If you wis	h to a	dd additional non-patent literature document citation information p	lease click the Add I	outton Add	
		EXAMINER SIGNATURE			
Examine	Signa	Mure /Alana Harris	Date Considered	12 June 2011	
*EXAMIN	IER: In	itial if reference donsidered, whether or not citation is in conforma	ance with MPEP 609	. Draw line through a	

1 See Kind Codes of USPTO Patent Documents at www\_USPTO\_GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3) a For Japanese plant documents, his en idication of the typer of the Emproval proced the serial number of the plant document. 4 Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST.16 if possible. 3 Applicant is to place a check mark here if English Inaurage translation is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.